A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment.

Trial Profile

A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Agomelatine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms REVIVE
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 24 May 2017 Results assessing the overall performance priority the antidepressants: vortioxetine, agomelatine and venlafaxine XR in patients from two randomised trials (SOLUTION and REVIVE), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 20 May 2015 Results comparing vortioxetine and other antidepressants presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top